Scinai Immunotherapeutics (SCNI) Competitors $2.01 +0.09 (+4.69%) Closing price 04/17/2025 03:42 PM EasternExtended Trading$2.04 +0.03 (+1.49%) As of 04/17/2025 05:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock SCNI vs. MTVA, OMGA, PRPH, MYNZ, SLXN, AIM, AYTU, GNPX, LIPO, and APLMShould you be buying Scinai Immunotherapeutics stock or one of its competitors? The main competitors of Scinai Immunotherapeutics include MetaVia (MTVA), Omega Therapeutics (OMGA), ProPhase Labs (PRPH), Mainz Biomed (MYNZ), Silexion Therapeutics (SLXN), AIM ImmunoTech (AIM), Aytu BioPharma (AYTU), Genprex (GNPX), Lipella Pharmaceuticals (LIPO), and Apollomics (APLM). These companies are all part of the "pharmaceutical products" industry. Scinai Immunotherapeutics vs. MetaVia Omega Therapeutics ProPhase Labs Mainz Biomed Silexion Therapeutics AIM ImmunoTech Aytu BioPharma Genprex Lipella Pharmaceuticals Apollomics MetaVia (NASDAQ:MTVA) and Scinai Immunotherapeutics (NASDAQ:SCNI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, media sentiment, community ranking, risk, institutional ownership and earnings. Is MTVA or SCNI more profitable? Scinai Immunotherapeutics' return on equity of 0.00% beat MetaVia's return on equity.Company Net Margins Return on Equity Return on Assets MetaViaN/A -189.12% -122.31% Scinai Immunotherapeutics N/A N/A -30.48% Does the media prefer MTVA or SCNI? In the previous week, MetaVia had 2 more articles in the media than Scinai Immunotherapeutics. MarketBeat recorded 4 mentions for MetaVia and 2 mentions for Scinai Immunotherapeutics. Scinai Immunotherapeutics' average media sentiment score of 0.50 beat MetaVia's score of 0.42 indicating that Scinai Immunotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MetaVia 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Scinai Immunotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger earnings & valuation, MTVA or SCNI? Scinai Immunotherapeutics has higher revenue and earnings than MetaVia. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMetaViaN/AN/A-$12.47MN/AN/AScinai Immunotherapeutics$452K4.15-$6.50M-$239.17-0.01 Do analysts rate MTVA or SCNI? MetaVia currently has a consensus target price of $12.00, indicating a potential upside of 1,523.82%. Given MetaVia's stronger consensus rating and higher probable upside, research analysts clearly believe MetaVia is more favorable than Scinai Immunotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MetaVia 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Scinai Immunotherapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk & volatility, MTVA or SCNI? MetaVia has a beta of 0.22, suggesting that its stock price is 78% less volatile than the S&P 500. Comparatively, Scinai Immunotherapeutics has a beta of 2.68, suggesting that its stock price is 168% more volatile than the S&P 500. Does the MarketBeat Community believe in MTVA or SCNI? MetaVia received 3 more outperform votes than Scinai Immunotherapeutics when rated by MarketBeat users. CompanyUnderperformOutperformMetaViaOutperform Votes3100.00% Underperform VotesNo VotesScinai ImmunotherapeuticsN/AN/A Do institutionals & insiders hold more shares of MTVA or SCNI? 1.4% of MetaVia shares are held by institutional investors. Comparatively, 58.4% of Scinai Immunotherapeutics shares are held by institutional investors. 1.1% of MetaVia shares are held by insiders. Comparatively, 60.9% of Scinai Immunotherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. SummaryScinai Immunotherapeutics beats MetaVia on 8 of the 13 factors compared between the two stocks. Get Scinai Immunotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SCNI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SCNI vs. The Competition Export to ExcelMetricScinai ImmunotherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.88M$2.84B$5.31B$7.35BDividend YieldN/A1.86%5.45%4.29%P/E Ratio-0.0130.4821.9417.82Price / Sales4.15441.91380.9597.68Price / CashN/A168.6838.2634.64Price / Book-0.203.466.453.98Net Income-$6.50M-$72.06M$3.22B$247.81M1 Month Performance-41.57%-16.76%-9.76%-7.91%1 Year Performance-56.87%-26.05%11.49%1.53% Scinai Immunotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SCNIScinai Immunotherapeutics1.1495 of 5 stars$2.01+4.7%N/A-55.9%$1.88M$452,000.00-0.0120Short Interest ↓Gap UpMTVAMetaVia2.0439 of 5 stars$0.81-56.0%$12.00+1,381.5%N/A$7.01MN/A0.008Analyst ForecastNews CoveragePositive NewsGap UpHigh Trading VolumeOMGAOmega Therapeutics1.7148 of 5 stars$0.13-21.8%$9.20+7,260.0%-94.8%$6.92M$8.10M-0.09120Gap UpPRPHProPhase Labs0.6548 of 5 stars$0.29-4.5%N/A-94.7%$6.87M$6.77M-0.23130Short Interest ↑MYNZMainz Biomed1.911 of 5 stars$3.34-0.9%$14.00+319.2%-91.1%$6.68M$893,991.00-0.0530Positive NewsGap DownSLXNSilexion TherapeuticsN/A$0.79-7.3%$5.00+532.9%N/A$6.65MN/A0.00N/APositive NewsAIMAIM ImmunoTech1.7633 of 5 stars$0.09-22.3%$2.75+2,908.8%-80.5%$6.61M$170,000.00-0.1920Gap DownHigh Trading VolumeAYTUAytu BioPharma0.8426 of 5 stars$1.04+4.0%N/A-63.6%$6.42M$77.23M-0.72160Positive NewsGap UpGNPXGenprex4.4094 of 5 stars$0.26-1.7%$10.00+3,746.2%-89.1%$6.28MN/A0.0020Short Interest ↓Positive NewsLIPOLipella Pharmaceuticals2.1673 of 5 stars$2.46+0.4%N/A-57.9%$6.27M$536,357.00-0.584Short Interest ↓APLMApollomics1.6937 of 5 stars$5.55-1.4%$200.00+3,503.6%-88.3%$6.03M$1.22M0.0045Positive NewsGap Down Related Companies and Tools Related Companies MetaVia Alternatives Omega Therapeutics Alternatives ProPhase Labs Alternatives Mainz Biomed Alternatives Silexion Therapeutics Alternatives AIM ImmunoTech Alternatives Aytu BioPharma Alternatives Genprex Alternatives Lipella Pharmaceuticals Alternatives Apollomics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SCNI) was last updated on 4/19/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scinai Immunotherapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Scinai Immunotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SCNI Stock Free SCNI Stock Alerts